Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor.

Neef S, Steffens A, Pellicena P, Mustroph J, Lebek S, Ort KR, Schulman H, Maier LS.

J Mol Cell Cardiol. 2018 Feb;115:73-81. doi: 10.1016/j.yjmcc.2017.12.015. Epub 2017 Dec 30.


CaMKII inhibitors: from research tools to therapeutic agents.

Pellicena P, Schulman H.

Front Pharmacol. 2014 Feb 20;5:21. doi: 10.3389/fphar.2014.00021. eCollection 2014. Review.


Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation.

Chao LH, Pellicena P, Deindl S, Barclay LA, Schulman H, Kuriyan J.

Nat Struct Mol Biol. 2010 Mar;17(3):264-72. doi: 10.1038/nsmb.1751. Epub 2010 Feb 7.


Probing the function of heme distortion in the H-NOX family.

Olea C, Boon EM, Pellicena P, Kuriyan J, Marletta MA.

ACS Chem Biol. 2008 Nov 21;3(11):703-10. doi: 10.1021/cb800185h.


Protein-protein interactions in the allosteric regulation of protein kinases.

Pellicena P, Kuriyan J.

Curr Opin Struct Biol. 2006 Dec;16(6):702-9. Epub 2006 Oct 31. Review.


A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases.

Pirruccello M, Sondermann H, Pelton JG, Pellicena P, Hoelz A, Chernoff J, Wemmer DE, Kuriyan J.

J Mol Biol. 2006 Aug 11;361(2):312-26. Epub 2006 Jun 27.


High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.

Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, Kuriyan J.

Protein Sci. 2005 Dec;14(12):3135-9. Epub 2005 Oct 31.


Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases.

Pellicena P, Karow DS, Boon EM, Marletta MA, Kuriyan J.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12854-9. Epub 2004 Aug 23.


Spectroscopic characterization of the soluble guanylate cyclase-like heme domains from Vibrio cholerae and Thermoanaerobacter tengcongensis.

Karow DS, Pan D, Tran R, Pellicena P, Presley A, Mathies RA, Marletta MA.

Biochemistry. 2004 Aug 10;43(31):10203-11.


Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells.

Goldberg GS, Alexander DB, Pellicena P, Zhang ZY, Tsuda H, Miller WT.

J Biol Chem. 2003 Nov 21;278(47):46533-40. Epub 2003 Sep 11.


Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J.

Cancer Res. 2002 Aug 1;62(15):4236-43.


Coupling kinase activation to substrate recognition in SRC-family tyrosine kinases.

Pellicena P, Miller WT.

Front Biosci. 2002 Jan 1;7:d256-67. Review.


Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc.

Baniecki ML, McGrath WJ, McWhirter SM, Li C, Toledo DL, Pellicena P, Barnard DL, Thorn KS, Mangel WF.

Biochemistry. 2001 Oct 16;40(41):12349-56. Erratum in: Biochemistry 2002 Jan 8;41(1):430.


Processive phosphorylation of p130Cas by Src depends on SH3-polyproline interactions.

Pellicena P, Miller WT.

J Biol Chem. 2001 Jul 27;276(30):28190-6. Epub 2001 Jun 1.


Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.

Science. 2000 Sep 15;289(5486):1938-42.


Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites.

Pellicena P, Stowell KR, Miller WT.

J Biol Chem. 1998 Jun 19;273(25):15325-8.


Involvement of the alpha subunit of farnesyl-protein transferase in substrate recognition.

Pellicena P, Scholten JD, Zimmerman K, Creswell M, Huang CC, Miller WT.

Biochemistry. 1996 Oct 15;35(41):13494-500.


Supplemental Content

Loading ...
Support Center